The fees and costs outlined in the $26 billion opioid deal with Johnson & Johnson’s Janssen Pharmaceuticals and three distributors are a mix of common benefit fees, contingency fees and payments to the states for outside counsel. One law professor said, “it’s not like the lawyers are going to be impoverished.”

       

Click Here To Read The Full Article